Mologic Strengthens Team With the Appointment of Mitch Brooker As General Manager

Commercial team expands to build on R&D successes and drive Company growth

Bedfordshire, UK, October 30th, 2017: Mologic, which develops powerful, personalised diagnostics to improve the lives of patients, today announced the appointment of Mitch Brooker as General Manager. The new role has been created to drive Company growth, building on Mologic’s current reputation as a successful R&D provider, and increasing its full-service offering. Mitch will use his skills and experience to help lead these changes and take products from conception through to manufacture and commercialisation.

Mitch has 18 years of experience in medical devices, gained primarily in point-of-care and cancer diagnostics. Previously, he has worked at Surgipath Europe, where he transformed its distributor offering to include manufacturing capabilities, and Leica Biosystems, where he completed the integration of Surgipath Europe, following its acquisition. Mitch also led global projects to develop innovative monitoring products at Philips and conducted seven years of research at Huntingdon Life Sciences.

Mark Davis, Co-founder and CEO at Mologic commented: “Mologic is committed to growth and recognises the need to invest in the right people with the necessary experience, to enable this. We’re delighted to have Mitch join us as General Manager; his experience in driving the required cultural change as we enter a new growth phase will be invaluable and will help lead us in increasing our service offering to cover the full spectrum, from idea to commercial product.”

Mitch Brooker, General Manager at Mologic commented: “Mologic has a tremendous team who has enjoyed great success in contract research and product development. I look forward to helping the Company build on these successes and unlock its full commercial potential.”

To find out more about the team at Mologic visit:

Media contact:
For more information please contact:
Sarah Jeffery, Zyme Communications
+44 (0)7771 730919

About Mologic

Mologic Ltd develops powerful, personalised diagnostics to improve the lives of patients. With a scientific team expert in translating science into practical solutions, the Company delivers technology where it is needed, to improve patient care and quality of life, breaking new ground in exciting fields of research. Mologic is focused on collaboration, partnerships and diversity and its innovative approach has generated an advanced portfolio of accurate and reliable point of care diagnostic tools for a variety of conditions, including COPD, diabetes, sepsis, UTIs, malignancies, inflammatory and respiratory conditions, and renal disease.

Led by co-founders Paul Davis, CSO, and Mark Davis, CEO, the Company’s broad range of skills and experience covers services from innovation to manufacture, including molecular engineering, assay and reagent development, clinical evaluation, antibodies, research and IP. Mologic’s low-volume manufacturing facility (ISO13485 certified) enables the business to take on almost any project challenge, irrespective of size, complexity or stage. Through professional partnerships, products have achieved high volume manufacturing, distribution and regulatory support globally.

Mologic’s interests extend beyond human healthcare, with active programs in agricultural diagnostics, large animal studies and vaccine innovation, successfully translating their advances in patient technology to other sectors.

Back to news